checkAd
    Startseite > Aktien > Mirum Pharmaceuticals > Nachrichten
    Mirum Pharmaceuticals Aktie
    24,200
     
    EUR
    +1,68 %
    +0,400 EUR
    Letzter Kurs 05.06.24 Tradegate
    24,000
     
    EUR
    252 STK
    Geldkurs 13:59:46
    24,400
     
    EUR
    250 STK
    Briefkurs 13:59:46
    ISIN: US6047491013 · WKN: A2PM29 · SYM: 08D · USA

    Neueste Nachrichten

    Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
    05.06.24 · Business Wire (engl.) · Mirum Pharmaceuticals
    Mirum Pharmaceuticals: positive CHMP-Stellungnahme für LIVMARLI (Maralixibat) als orale Lösung zur Behandlung von PFIC bei Patienten ab einem Alter von drei Monaten
    31.05.24 · Business Wire (dt.) · Mirum Pharmaceuticals
    Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
    31.05.24 · Business Wire (engl.) · Mirum Pharmaceuticals
    Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
    29.05.24 · Business Wire (engl.) · Mirum Pharmaceuticals
    Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting
    18.05.24 · Business Wire (engl.) · Mirum Pharmaceuticals
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    11.05.24 · Business Wire (engl.) · Mirum Pharmaceuticals
    Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
    08.05.24 · Business Wire (engl.) · Mirum Pharmaceuticals
    Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
    07.05.24 · Business Wire (engl.) · Mirum Pharmaceuticals
    Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
    07.05.24 · Business Wire (engl.) · Mirum Pharmaceuticals
    Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
    01.05.24 · Business Wire (engl.) · Mirum Pharmaceuticals
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    11.04.24 · Business Wire (engl.) · Mirum Pharmaceuticals
    Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
    02.04.24 · Business Wire (engl.) · Mirum Pharmaceuticals